Literature DB >> 15645606

Bevacizumab.

Mohamed Muhsin, Joanne Graham, Peter Kirkpatrick.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15645606     DOI： 10.1038/nrd1601

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN： 1474-1776            Impact factor:   84.694


× No keyword cloud information.
  23 in total

1.  Extending foldamer design beyond α-helix mimicry: α/β-peptide inhibitors of vascular endothelial growth factor signaling.

Authors:  Holly S Haase; Kimberly J Peterson-Kaufman; Sheeny K Lan Levengood; James W Checco; William L Murphy; Samuel H Gellman
Journal:  J Am Chem Soc       Date:  2012-05-01       Impact factor: 15.419

Review 2.  Bevacizumab for glioblastoma: current indications, surgical implications, and future directions.

Authors:  Brandyn A Castro; Manish K Aghi
Journal:  Neurosurg Focus       Date:  2014-12       Impact factor: 4.047

3.  Presence of Histopathological Treatment Effects at Resection of Recurrent Glioblastoma: Incidence and Effect on Outcome.

Authors:  Cecilia L Dalle Ore; Ankush Chandra; Jonathan Rick; Darryl Lau; Maryam Shahin; Alan T Nguyen; Michael McDermott; Mitchel S Berger; Manish K Aghi
Journal:  Neurosurgery       Date:  2019-12-01       Impact factor: 4.654

4.  Histone deacetylase inhibitors decrease intra-abdominal adhesions with one intraoperative dose by reducing peritoneal fibrin deposition pathways.

Authors:  Michael R Cassidy; Alan C Sherburne; Holly K Sheldon; Melanie L Gainsbury; Stanley Heydrick; Arthur F Stucchi
Journal:  Surgery       Date:  2013-11-14       Impact factor: 3.982

5.  A fluorescence polarization assay for identifying ligands that bind to vascular endothelial growth factor.

Authors:  Kimberly J Peterson; Jack D Sadowsky; Elizabeth A Scheef; Soumen Pal; Katerina D Kourentzi; Richard C Willson; Emery H Bresnick; Nader Sheibani; Samuel H Gellman
Journal:  Anal Biochem       Date:  2008-03-28       Impact factor: 3.365

Review 6.  Latest developments in our understanding of the pathogenesis of mesothelioma and the design of targeted therapies.

Authors:  Angela Bononi; Andrea Napolitano; Harvey I Pass; Haining Yang; Michele Carbone
Journal:  Expert Rev Respir Med       Date:  2015-08-26       Impact factor: 3.772

7.  Bevacizumab (BVZ)-associated toxicities in children with recurrent central nervous system tumors treated with BVZ and irinotecan (CPT-11): a Pediatric Brain Tumor Consortium Study (PBTC-022).

Authors:  Jason Fangusaro; Sridharan Gururangan; Tina Young Poussaint; Roger E McLendon; Arzu Onar-Thomas; Katherine E Warren; Shengjie Wu; Roger J Packer; Anu Banerjee; Richard J Gilbertson; Regina Jakacki; Amar Gajjar; Stewart Goldman; Ian F Pollack; Henry S Friedman; James M Boyett; Larry E Kun; Maryam Fouladi
Journal:  Cancer       Date:  2013-09-19       Impact factor: 6.860

Review 8.  Off-label use of bevacizumab for the treatment of age-related macular degeneration: what is the evidence?

Authors:  Focke Ziemssen; Salvatore Grisanti; Karl Ulrich Bartz-Schmidt; Martin S Spitzer
Journal:  Drugs Aging       Date:  2009       Impact factor: 3.923

9.  Design, synthesis and biological evaluation of substituted pyrrolo[2,3-d]pyrimidines as multiple receptor tyrosine kinase inhibitors and antiangiogenic agents.

Authors:  Aleem Gangjee; Ojas A Namjoshi; Jianming Yu; Michael A Ihnat; Jessica E Thorpe; Linda A Warnke
Journal:  Bioorg Med Chem       Date:  2008-04-14       Impact factor: 3.641

Review 10.  Vascular stenosis in a child with visual pathway glioma treated with bevacizumab: a case report and review of literature.

Authors:  Chiara Pilotto; Ismail Beshlawi; Adam Thomas; Richard G Grundy
Journal:  Childs Nerv Syst       Date:  2017-12-16       Impact factor: 1.475
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.